Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin analog delivered the highest weight loss—9.8%—at Week 28.
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
